1. CB11, a novel purine-based PPARɣ ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells
- Author
-
Da-Won Hong, Sung Hee Hong, Tae Woo Kim, and Joung Whan Park
- Subjects
Cancer Research ,Cell cycle checkpoint ,Lung Neoplasms ,Cancer therapy ,Apoptosis ,Cell Cycle Proteins ,Ataxia Telangiectasia Mutated Proteins ,Ligands ,Radiation Tolerance ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Onium Compounds ,Carcinoma, Non-Small-Cell Lung ,Adipocytes ,Anilides ,RNA, Small Interfering ,Receptor ,Cytotoxicity ,Luciferases ,Membrane Potential, Mitochondrial ,Mice, Inbred BALB C ,NADPH oxidase ,biology ,Cell Death ,Chemistry ,Caspase 3 ,Imidazoles ,Cell Differentiation ,3T3 Cells ,Caspase 9 ,Tumor Burden ,Oncology ,030220 oncology & carcinogenesis ,Female ,Lung cancer ,Signal Transduction ,Programmed cell death ,Epithelial-Mesenchymal Transition ,Mice, Nude ,Article ,03 medical and health sciences ,Lactate dehydrogenase ,Cell Line, Tumor ,medicine ,Animals ,Humans ,L-Lactate Dehydrogenase ,Cell Cycle Checkpoints ,medicine.disease ,PPAR gamma ,Purines ,biology.protein ,Cancer research ,Thiazolidinediones ,Tumor Suppressor Protein p53 ,Reactive Oxygen Species ,Azo Compounds ,DNA Damage - Abstract
Background Peroxisome proliferator-activated receptor γ (PPARγ) agonists frequently induce cell death in human non-small-cell lung cancer (NSCLC) cells. However, majority of NSCLC patients acquire resistance after cancer therapy, and it is still unclear. Methods In this study we investigated the apoptotic mechanism and the anti-cancer effects of a novel purine-based PPARγ agonist, CB11 (8-(2-aminophenyl)-3-butyl-1,6,7-trimethyl-1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione), on human NSCLC cells. CB11 mediates PPARγ-dependent cell death, reactive oxygen species (ROS) production, mitochondrial membrane potential (MMP) collapse, cell cycle arrest, lactate dehydrogenase (LDH) cytotoxicity, and caspase-3 activity in human NSCLC cells. Results CB11 causes cell death via ROS-mediated ATM-p53-GADD45α signalling in human NSCLC cells, and diphenyleneiodonium (DPI), an NADPH oxidase inhibitor, decreases cell death by inhibiting CB11-mediated ATM signalling. In a xenograft experiment, CB11 dramatically reduced tumour volume when compared to a control group. Furthermore, CB11 induced cell death by inhibiting epithelial-to-mesenchymal transition (EMT) under radiation exposure in radiation-resistant human NSCLC cells. However, PPARγ deficiency inhibited cell death by blocking the ATM-p53 axis in radiation/CB11-induced radiation-resistant human NSCLC cells. Conclusions Taken together, our results suggest that CB11, a novel PPARγ agonist, may be a novel anti-cancer agent, and it could be useful in a therapeutic strategy to overcome radio-resistance in radiation-exposed NSCLC.
- Published
- 2020